Preliminarily, Appelbaum notes that Xenova's 58% success rate is unusually high. "In any one round [of addiction trials] you have a 10-20% success rate, and it's usually many rounds before that number becomes higher. Ultimately, 58% is a big step forward," he explains.
"If it's successful it could be extremely helpful," Appelbaum continues. "There is no doubt that some people have a heightened susceptibility to general addiction. If we have the genetic ability to medicate, vaccinate, or block a specific abnormality, that would have an even broader impact."
Beyond preventing relapse, Janda suggested treatments like these anti-drug vaccines could possibly even counter-act overdoses.
However, single substance users are uncommon, as Appelbaum notes: "what we really should look at is a vaccine targeted against multiple addictions."
Ultimately, Janda and many others note "If you don't have the desire [to stop addiction], it's useless. There are so many drugs out there; you'll just find another drug;" vaccine or no vaccine.